CADLCandel Therapeutics, Inc.

Nasdaq candeltx.com


$ 8.59 $ 0.75 (9.62 %)    

Tuesday, 28-May-2024 15:59:01 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 8.55
$ 7.85
$ 8.55 x 450
$ 8.61 x 200
$ 7.40 - $ 9.15
$ 0.66 - $ 14.30
1,720,008
na
249.64M
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-05-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 09-08-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 candel-therapeutics-to-present-data-from-its-phase-2-clinical-trial-of-can-2409-at-asco

As of the data cut-off date, CAN-2409 treatment in NSCLC continued to exhibit a favorable safety and tolerability profile

 candel-therapeutics-q1-eps-028-up-from-030-yoy

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.28) per share. This is a 6.67 percent increase over losses o...

 why-fastenal-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...

 whats-going-on-with-candel-therapeutics-stock

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designati...

 candel-therapeutics-receives-fda-orphan-drug-designation-for-can-2409-for-the-treatment-of-pancreatic-cancer

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developi...

 whats-going-on-with-candel-therapeutics-stock-on-friday

Candel Therapeutics sees surge in shares amid robust volume, buoyed by promising interim data from CAN-2409 phase 2 trial for n...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION